New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients

被引:191
作者
Sia, IG
Patel, R
机构
[1] Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA
关键词
D O I
10.1128/CMR.13.1.83-121.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In the past three decades since the inception of human organ transplantation, cytomegalovirus (CMV) has gained increasing clinical import because it is a common pathogen in the immunocompromised transplant recipient. Patients may suffer from severe manifestations of this infection along with the threat of potential fatality. Additionally, the dynamic evolution of immunosuppressive and antiviral agents has brought forth changes in the natural history of CMV infection and disease. Transplant Physicians now face the daunting task of recognizing and managing the changing spectrum of CMV infection and its consequences in the organ recipient. For the microbiology laboratory, the emphasis has been geared toward the development of more sophisticated detection assays, including methods to detect emerging antiviral resistance. The discovery of novel antiviral chemotherapy is an important theme of clinical research. Investigations have also focused on preventative measures for CMV disease in the solid-organ transplant population. In all, while much has been achieved in the overall management of CMV infection, the current understanding of CMV pathogenesis and therapy still leaves much to be learned before success can be claimed.
引用
收藏
页码:83 / +
页数:41
相关论文
共 516 条
[51]  
BRAINARD JA, 1994, TRANSPLANTATION, V57, P1753, DOI 10.1097/00007890-199457120-00012
[52]   EVALUATION OF SQ-34,514 - PHARMACOKINETICS AND EFFICACY IN EXPERIMENTAL HERPESVIRUS INFECTIONS IN MICE [J].
BRAITMAN, A ;
SWERDEL, MR ;
OLSEN, SJ ;
TUOMARI, AV ;
LYNCH, JS ;
BLUE, B ;
MICHALIK, T ;
FIELD, AK ;
BONNER, DP ;
CLARK, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (07) :1464-1468
[53]   Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients [J].
Brennan, DC ;
Garlock, KA ;
Singer, GG ;
Schnitzler, MA ;
Lippmann, BJ ;
Buller, RS ;
Gaudreault-Keener, M ;
Lowell, JA ;
Shenoy, S ;
Howard, TK ;
Storch, GA .
TRANSPLANTATION, 1997, 64 (12) :1843-1846
[54]  
Brennan DC, 1997, J AM SOC NEPHROL, V8, P118
[55]  
BUHLES WC, 1988, REV INFECT DIS, V10, pS495
[56]  
BURDELSKI M, 1987, TRANSPLANT P, V19, P3277
[57]   CYTOMEGALOVIRUS DETECTION IN BONE-MARROW TRANSPLANT PATIENTS WITH IDIOPATHIC PNEUMONITIS - A CLINICOPATHOLOGICAL STUDY OF THE CLINICAL UTILITY OF THE POLYMERASE CHAIN-REACTION ON OPEN LUNG-BIOPSY SPECIMEN TISSUE [J].
BURGART, LJ ;
HELLER, MJ ;
REZNICEK, MJ ;
GREINER, TC ;
TENEYCK, CJ ;
ROBINSON, RA .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1991, 96 (05) :572-576
[58]   Evaluation of a leukocyte stabilization reagent for use in the cytomegalovirus pp65 antigenemia assay [J].
Bush, CE ;
Sluchak-Carlsen, JA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (11) :3410-3411
[59]   SEMIQUANTITATIVE MEASUREMENT OF CYTOMEGALOVIRUS DNA IN LUNG AND HEART-LUNG TRANSPLANT PATIENTS BY INVITRO DNA AMPLIFICATION [J].
CAGLE, PT ;
BUFFONE, G ;
HOLLAND, VA ;
SAMO, T ;
DEMMLER, GJ ;
NOON, GP ;
LAWRENCE, EC .
CHEST, 1992, 101 (01) :93-96
[60]   CYTOMEGALOVIRUS INFECTIONS IN DIFFERENT GROUPS OF PAEDIATRIC PATIENTS [J].
CARLSTROM, G ;
JALLING, B .
ACTA PAEDIATRICA SCANDINAVICA, 1970, 59 (03) :303-+